Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

COM:AGIOS

Agios Pharmaceuticals, Inc.

Last Close

55.54

22/11 17:09

Market Cap

3.15B

Beta: -

Volume Today

120.92K

Avg: -

Financials Not Available